SANTA CLARA, Calif. -- (BUSINESS WIRE) -- XenoPort, Inc. (Nasdaq:XNPT) announced today that Richard Kim, M.D., has been appointed senior vice president, clinical development and medical affairs, and chief medical officer. Dr. Kim joined XenoPort in July 2013 as vice president of medical affairs, supporting XenoPort’s launch of HORIZANT® (gabapentin enacarbil) Extended-Release Tablets. Dr. Kim has more than a decade of experience in both clinical development and medical affairs, most recently as vice president of clinical development and head of the multiple sclerosis therapeutic area at Elan Pharmaceuticals, Inc.
"We are excited to have Richard take an expanded role as we advance XP23829 into planned Phase 2 development," said Ronald W. Barrett, Ph.D., chief executive officer of XenoPort. “Richard’s experience in Phase 1 through 4 clinical development, particularly in autoimmune diseases such as multiple sclerosis, is a valuable addition to the XenoPort team.”
In his previous position at Elan, Dr. Kim was joint program team leader for natalizumab (TYSABRI), which is approved globally for treatment of multiple sclerosis and approved for treatment of Crohn’s Disease in the United States. Prior to Elan, he was the global medical affairs director for natalizumab at Biogen Idec Inc., during which he played an integral role in successfully re-launching TYSABRI in the United States, as well as its subsequent global launch. Prior to Biogen Idec, he was the medical director responsible for the cladribine Phase 3 program at EMD Serono, Inc. He began his industry career more than a decade ago at Purdue Pharma L.P., where he worked on the early development of buprenorphine transdermal patch (BUTRANS).
Dr. Kim received his medical degree from Tulane University, completed his neurology residency training at Stanford University, and is a diplomat of the American Board of Psychiatry and Neurology.
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for psoriasis and/or relapsing forms of multiple sclerosis (MS). REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort's pipeline of product candidates also includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson's disease. To learn more about XenoPort, please visit the website at www.XenoPort.com.
This press release contains “forward-looking” statements, including, without limitation, all statements related to the potential suitability of XP23829 as a treatment for moderate-to-severe plaque psoriasis and/or relapsing forms of MS, and advancing XP23829 into planned Phase 2 development. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “planned,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon XenoPort's current expectations. Forward-looking statements involve risks and uncertainties. XenoPort's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: risks related to XenoPort’s ability to successfully advance XP23829 development and to conduct or initiate clinical trials in the anticipated timeframes, or at all; the difficulty and uncertainty of pharmaceutical product development and the uncertain results and timing of clinical trials and other studies, including the risk that success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and that the results of clinical trials by other parties may not be indicative of the results in trials that XenoPort may conduct; the uncertainty of the U.S. Food and Drug Administration’s (FDA’s) review process and other regulatory requirements; XenoPort's need for and the availability of resources to develop XenoPort's product candidates and support XenoPort's operations; and the uncertain therapeutic and commercial value of XenoPort's product candidates. These and other risk factors are discussed under the heading "Risk Factors" in XenoPort’s prospectus supplement, filed with the Securities and Exchange Commission under Rule 424(b)(5) on January 24, 2014. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.